Lancet Hiv最新文献

筛选
英文 中文
Correction to Lancet HIV 2025; published online June 11. https://doi.org/10.1016/S2352-3018(25)00158-4. 《柳叶刀HIV 2025》修正;6月11日在网上发表。https://doi.org/10.1016/s2352 - 3018(25) 00158 - 4。
IF 16.1 1区 医学
Lancet Hiv Pub Date : 2025-09-05 DOI: 10.1016/s2352-3018(25)00266-8
{"title":"Correction to Lancet HIV 2025; published online June 11. https://doi.org/10.1016/S2352-3018(25)00158-4.","authors":"","doi":"10.1016/s2352-3018(25)00266-8","DOIUrl":"https://doi.org/10.1016/s2352-3018(25)00266-8","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"35 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145018251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epstein-Barr virus and cytomegalovirus co-infections and mortality risk in patients with HIV-associated cryptococcal meningitis: a post-hoc analysis of a prospective nested cohort in the AMBITION-cm randomised controlled trial. eb病毒和巨细胞病毒合并感染与hiv相关隐球菌性脑膜炎患者的死亡风险:一项对AMBITION-cm随机对照试验前瞻性巢式队列的事后分析
IF 16.1 1区 医学
Lancet Hiv Pub Date : 2025-09-04 DOI: 10.1016/s2352-3018(25)00163-8
Jayne Ellis,Elisabetta Groppelli,Ronan Doyle,David S Lawrence,David B Meya,David R Boulware,Henry C Mwandumba,Cecilia Kanyama,Mina C Hosseinipour,Graeme Meintjes,Conrad Muzoora,Mosepele Mosepele,Chiratidzo E Ndhlovu,Thomas S Harrison,Joseph N Jarvis,
{"title":"Epstein-Barr virus and cytomegalovirus co-infections and mortality risk in patients with HIV-associated cryptococcal meningitis: a post-hoc analysis of a prospective nested cohort in the AMBITION-cm randomised controlled trial.","authors":"Jayne Ellis,Elisabetta Groppelli,Ronan Doyle,David S Lawrence,David B Meya,David R Boulware,Henry C Mwandumba,Cecilia Kanyama,Mina C Hosseinipour,Graeme Meintjes,Conrad Muzoora,Mosepele Mosepele,Chiratidzo E Ndhlovu,Thomas S Harrison,Joseph N Jarvis, ","doi":"10.1016/s2352-3018(25)00163-8","DOIUrl":"https://doi.org/10.1016/s2352-3018(25)00163-8","url":null,"abstract":"BACKGROUNDHIV-associated cryptococcal meningitis case fatality remains greater than 25%. Co-prevalent infections might contribute to poor outcomes. We aimed to ascertain the prevalence and the clinical significance of Epstein-Barr virus (EBV) and cytomegalovirus co-infections in patients with cryptococcal meningitis to guide potential therapeutic interventions.METHODSWe conducted a post-hoc analysis of a prospective cohort using plasma and cerebrospinal fluid (CSF) samples collected in the AMBITION-cm randomised trial. AMBITION-cm was done at seven hospital sites across five African countries (Botswana, Malawi, South Africa, Uganda, and Zimbabwe). The primary endpoint of the trial was all-cause mortality at 10 weeks. Quantitative PCR (qPCR) was used to measure baseline cytomegalovirus and EBV viral loads in these samples. Baseline demographic and clinical data including antiretroviral therapy status, and laboratory data including CD4 cell count, CSF white cell count, protein, glucose, and quantitative cryptococcal culture were captured in real time via an electronic medical records system. We assessed the prevalence of cytomegalovirus plasma viraemia and EBV plasma viraemia, and CNS co-infections, associations between cytomegalovirus and EBV co-infection status and baseline covariates, and associations with 2-week and 10-week mortality.FINDINGSBetween Jan 31, 2018, and Feb 18, 2021, among 811 participants enrolled, 60% were male, median age was 37 years (IQR 32-43), and median baseline CD4 count was 27 cells per μL (IQR 10-58). Cytomegalovirus plasma viraemia was present in 395 (49%) of 804 participants and EBV plasma viraemia was present in 585 (73%) participants. 39 (5%) of 707 participants had detectable cytomegalovirus in the CSF and 191 (27%) of 708 participants had detectable EBV. Cytomegalovirus plasma viraemia was associated with lower CD4 cell counts, less CSF inflammation, and higher CSF fungal burdens. Conversely, EBV plasma viraemia was associated with higher CD4 cell counts and more CSF inflammation. At 2 and 10 weeks, the risk of mortality was two times higher in participants with high-level cytomegalovirus plasma viraemia (≥1000 copies per mL) than in participants without cytomegalovirus plasma viraemia (adjusted odds ratio 2·31 [95% CI 1·12-4·75] at 2 weeks; 2·44 [1·33-4·45] at 10 weeks). EBV coinfections were not associated with increased mortality.INTERPRETATIONThese data indicate that cytomegalovirus might be an important copathogen in this context, and that cytomegalovirus viraemia represents a potentially modifiable risk factor to reduce mortality among adults with HIV-associated cryptococcal meningitis. Interventional trials are now required and planned to determine whether treatment of cytomegalovirus viraemia improves outcomes in advanced HIV disease.FUNDINGNational Institute for Health and Care Research, European and Developing Countries Clinical Trials Partnership, Medical Research Council, and Wellcome Trust.","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"21 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HIV-related mortality time trends among children and young adolescents on antiretroviral therapy by age, treatment duration, and region: a systematic review and meta-regression analysis. 在接受抗逆转录病毒治疗的儿童和青少年中,按年龄、治疗时间和地区划分的艾滋病毒相关死亡率趋势:一项系统回顾和荟萃回归分析
IF 16.1 1区 医学
Lancet Hiv Pub Date : 2025-09-02 DOI: 10.1016/s2352-3018(25)00168-7
Jiawei He,Edmond Brewer,Amanda Novotney,Austin Carter,Hilary Paul,Magdalene K Walters,Kemal Sherefa Oumer,Reshma Kassanjee,Joycelyn Dame,Sophie Desmonde,Brian Eley,Azar Kariminia,Denis Nash,Peter F Rebeiro,Vanessa Rouzier,Tavitiya Sudjaritruk,Kara Wools-Kaloustian,Constantin T Yiannoutsos,Marcel Yotebieng,Reed J D Sorensen,Christopher J L Murray,Simon I Hay,Aleksandr Aravkin,Abraham Flaxman,Peng Zheng,Hmwe H Kyu
{"title":"HIV-related mortality time trends among children and young adolescents on antiretroviral therapy by age, treatment duration, and region: a systematic review and meta-regression analysis.","authors":"Jiawei He,Edmond Brewer,Amanda Novotney,Austin Carter,Hilary Paul,Magdalene K Walters,Kemal Sherefa Oumer,Reshma Kassanjee,Joycelyn Dame,Sophie Desmonde,Brian Eley,Azar Kariminia,Denis Nash,Peter F Rebeiro,Vanessa Rouzier,Tavitiya Sudjaritruk,Kara Wools-Kaloustian,Constantin T Yiannoutsos,Marcel Yotebieng,Reed J D Sorensen,Christopher J L Murray,Simon I Hay,Aleksandr Aravkin,Abraham Flaxman,Peng Zheng,Hmwe H Kyu","doi":"10.1016/s2352-3018(25)00168-7","DOIUrl":"https://doi.org/10.1016/s2352-3018(25)00168-7","url":null,"abstract":"BACKGROUNDPast cohort studies have examined mortality among children and young adolescents (aged 0-14 years) who have received antiretroviral therapy (ART), but no systematic reviews have been undertaken to synthesise these findings. Our study aims to provide the most comprehensive global estimates of paediatric mortality among children and adolescents receiving ART.METHODSFor this systematic review and meta-regression analysis, we searched PubMed and Embase from Jan 1, 1990 to July 31, 2024 for studies reporting mortality among children and young adolescents living with HIV who were on ART. We employed the meta-regression with Bayesian priors, regularisation, and trimming tool, developed for the Global Burden of Disease study 2019, for meta-regression analysis to estimate on-ART mortality by region, CD4 cell count or percentage, age, sex, and treatment duration. We assessed the robustness of our results by doing a sensitivity analysis, restricting it to studies of good quality using the quality assessment tool adapted from the Newcastle-Ottawa Scale and the National Heart, Lung, and Blood Institute. This study has been registered with PROSPERO (CRD42022382702).FINDINGSOur literature search identified 7588 records, of which 5853 were determined relevant for title and abstract review. Following screening, 1068 records were selected for full-text assessment. We included 84 studies in our systematic review, of which 66 were included in the meta-regression analysis. Our analysis indicated that HIV-related mortality for all children and young adolescents (aged 0-14 years) decreased over time, between 2000 and 2020 globally, after adjusting for region, baseline CD4 cell count, age, treatment duration, and sex. Additionally, HIV-related mortality decreased with increasing CD4 cell count at ART initiation and longer treatment duration. There have been considerable geographical variations in the risk of mortality. Among the high-mortality group in 2020 (ART duration <6 months, age <1 year, male, and the lowest CD4 cell counts), HIV-related mortality across regions ranged from 11·7 deaths (95% CI 8·3-15·4) per 100 person-years in eastern Sub-Saharan Africa to 72·0 deaths (47·1-98·1) per 100 person-years in Asia-Pacific. Among the low-mortality group in 2020 (ART duration ≥1 year, age 5-9 years, female, and the highest CD4 cell counts), HIV-related mortality ranged from 0·09 deaths (0·07-0·10) per 100 person-years in eastern Sub-Saharan Africa to 0·20 deaths (0·03-0·80) per 100 person-years in Latin America and the Caribbean.INTERPRETATIONA comprehensive approach to paediatric HIV care is essential to improving outcomes for children and young adolescents living with HIV. Clinically, this approach includes strengthening the prevention of vertical transmission, ensuring early diagnosis in infants, and initiating treatment promptly-ideally at higher CD4 cell counts. From a policy perspective, health systems need to address disparities in treatment access and o","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"72 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145003208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retiring the language of first-line and second-line ART. 淘汰一线和二线ART的语言。
IF 13 1区 医学
Lancet Hiv Pub Date : 2025-09-01 Epub Date: 2025-06-05 DOI: 10.1016/S2352-3018(25)00137-7
Marco Vitoria, Graeme Meintjes, Nathan Ford, Lisa Frigati, Nandita Sugandhi, Alexandra Calmy
{"title":"Retiring the language of first-line and second-line ART.","authors":"Marco Vitoria, Graeme Meintjes, Nathan Ford, Lisa Frigati, Nandita Sugandhi, Alexandra Calmy","doi":"10.1016/S2352-3018(25)00137-7","DOIUrl":"10.1016/S2352-3018(25)00137-7","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e608-e610"},"PeriodicalIF":13.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7617779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Activists step in to deliver PEP and PrEP in Mexico. 积极分子在墨西哥提供PEP和PrEP。
IF 13 1区 医学
Lancet Hiv Pub Date : 2025-09-01 Epub Date: 2025-05-29 DOI: 10.1016/S2352-3018(25)00134-1
Roger Pebody
{"title":"Activists step in to deliver PEP and PrEP in Mexico.","authors":"Roger Pebody","doi":"10.1016/S2352-3018(25)00134-1","DOIUrl":"10.1016/S2352-3018(25)00134-1","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e614"},"PeriodicalIF":13.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Due south: navigating volatile health research landscapes. 正南:导航不稳定的健康研究景观。
IF 16.1 1区 医学
Lancet Hiv Pub Date : 2025-09-01 DOI: 10.1016/s2352-3018(25)00245-0
Stephan Rabie,Hlombekazi Sybil Majokweni,Lwandile Tokwe,Tafadzwa Mautsa,John Joska
{"title":"Due south: navigating volatile health research landscapes.","authors":"Stephan Rabie,Hlombekazi Sybil Majokweni,Lwandile Tokwe,Tafadzwa Mautsa,John Joska","doi":"10.1016/s2352-3018(25)00245-0","DOIUrl":"https://doi.org/10.1016/s2352-3018(25)00245-0","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"29 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144995667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunology of infants who are HIV-exposed uninfected in the parental combination antiretroviral therapy era. 在父母联合抗逆转录病毒治疗时代暴露于hiv的未感染婴儿的免疫学。
IF 13 1区 医学
Lancet Hiv Pub Date : 2025-08-27 DOI: 10.1016/S2352-3018(25)00184-5
Melanie A Gasper, Anna-Ursula Happel, Sonwabile Dzanibe, Jennifer Slyker, Heather B Jaspan
{"title":"Immunology of infants who are HIV-exposed uninfected in the parental combination antiretroviral therapy era.","authors":"Melanie A Gasper, Anna-Ursula Happel, Sonwabile Dzanibe, Jennifer Slyker, Heather B Jaspan","doi":"10.1016/S2352-3018(25)00184-5","DOIUrl":"https://doi.org/10.1016/S2352-3018(25)00184-5","url":null,"abstract":"<p><p>The introduction and programmatic scale-up of universal antiretroviral therapy in pregnancy (option B and option B+) and the subsequent universal test-and-treat approaches have dramatically reduced infant HIV-1 acquisitions globally, with a parallel increase in the number of infants who are HIV-exposed uninfected (HEU). Although infants who are HEU have historically had higher risk of morbidity and mortality than infants who are HIV unexposed, effective parental viral suppression has enabled people living with HIV to carry healthier pregnancies and realise the benefits of optimised feeding practices that support the transfer of key nutrients and immune factors through their parent's own milk. However, residual, heightened inflammation, altered gut microbiome, and differences in innate and adaptive immunology in infants who are HEU remain, and might contribute to persistent, heightened infectious morbidity. Parental HIV infection continues to influence child health in the option B and option B+ era; future research is needed to uncover underlying mechanisms and long-term implications of these strategies.</p>","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":""},"PeriodicalIF":13.0,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144975015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial 比替格拉韦、恩曲他滨和替诺福韦阿拉那胺与利托那韦增强的基于蛋白酶抑制剂的抗逆转录病毒治疗和海地二线治疗的病毒抑制:一项开放标签、随机、非劣效性试验
IF 16.1 1区 医学
Lancet Hiv Pub Date : 2025-08-27 DOI: 10.1016/s2352-3018(25)00130-4
Patrice Severe MD, Samuel Pierre MD, Fabienne Homeus MD, Jean Bernard Marc MD, Letizia Trevisi PhD, Maria Linda Aristhomene BS, Guirlaine R Bernadin BS, Kerlyne Lavoile BS, Vanessa Rivera BS, Carl Frederic Duchatellier MD, Marie Josee Joseph BS, John Wu MBA, Vanessa Rouzier MD, Fabiola Preval BS, Evens Jean BS, Jodany Bernadin BS, Abigail Zion BS, Guyrlaine Pierre Louis Forestal PharmD, Santiago Avila-Rios PhD, Claudia Garcia Morales PhD, Adina Zhang MS, Dennis Israelski MD, Alexandra Apollon BS, Emelyne Dumont BS, Elizabeth Fox PhD, Pierre-Yves Cremieux PhD, Prof Jean W Pape MD, Sean E Collins MD, Bernard Liautaud MD, Prof Paul E Sax MD, Serena P Koenig MD
{"title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial","authors":"Patrice Severe MD, Samuel Pierre MD, Fabienne Homeus MD, Jean Bernard Marc MD, Letizia Trevisi PhD, Maria Linda Aristhomene BS, Guirlaine R Bernadin BS, Kerlyne Lavoile BS, Vanessa Rivera BS, Carl Frederic Duchatellier MD, Marie Josee Joseph BS, John Wu MBA, Vanessa Rouzier MD, Fabiola Preval BS, Evens Jean BS, Jodany Bernadin BS, Abigail Zion BS, Guyrlaine Pierre Louis Forestal PharmD, Santiago Avila-Rios PhD, Claudia Garcia Morales PhD, Adina Zhang MS, Dennis Israelski MD, Alexandra Apollon BS, Emelyne Dumont BS, Elizabeth Fox PhD, Pierre-Yves Cremieux PhD, Prof Jean W Pape MD, Sean E Collins MD, Bernard Liautaud MD, Prof Paul E Sax MD, Serena P Koenig MD","doi":"10.1016/s2352-3018(25)00130-4","DOIUrl":"https://doi.org/10.1016/s2352-3018(25)00130-4","url":null,"abstract":"Patients on second-line protease inhibitor-based regimens in low-income and middle-income countries have high rates of nucleoside reverse transcriptase inhibitor (NRTI) resistance, but access to testing is scarce. We aimed to assess the efficacy of combination oral bictegravir, emtricitabine, and tenofovir alafenamide in this population.","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"33 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144924697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimised second-line regimens in the public health approach 优化二线公共卫生方案
IF 16.1 1区 医学
Lancet Hiv Pub Date : 2025-08-27 DOI: 10.1016/s2352-3018(25)00186-9
Nicholas I Paton
{"title":"Optimised second-line regimens in the public health approach","authors":"Nicholas I Paton","doi":"10.1016/s2352-3018(25)00186-9","DOIUrl":"https://doi.org/10.1016/s2352-3018(25)00186-9","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"25 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144924694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A moment of reckoning 清算的时刻
IF 16.1 1区 医学
Lancet Hiv Pub Date : 2025-08-27 DOI: 10.1016/s2352-3018(25)00244-9
The Lancet HIV
{"title":"A moment of reckoning","authors":"The Lancet HIV","doi":"10.1016/s2352-3018(25)00244-9","DOIUrl":"https://doi.org/10.1016/s2352-3018(25)00244-9","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"60 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144924700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信